Investigational New Drugs 1991-11-01

Phase II evaluation of bisantrene in refractory multiple myeloma. A Southwest Oncology Group study.

B G Durie, J Crowley, C A Coltman, R A Chapman, S P Balcerzk, J D Bonnet, D A Lipschitz, R L Stephens, B D Cheson

Index: Invest. New Drugs 9(4) , 329-31, (1991)

Full Text: HTML

Related Compounds

In vitro effects of bisantrene on fresh clonogenic leukemia cells: a preliminary study on 15 cases.

1990-01-01

[Haematologica 75(6) , 527-31, (1990)]

Phase II trial of Bisantrene for metastatic melanoma: an Illinois cancer council study.

1991-01-01

[Med. Pediatr. Oncol. 19(2) , 126-8, (1991)]

Retroviral transfer of the human MDR1 gene confers resistance to bisantrene-specific hematotoxicity.

2014-04-29

[Clin. Cancer Res. 2(6) , 973-80, (1996)]

Synthesis, DNA-damaging and cytotoxic properties of novel topoisomerase II-directed bisantrene analogues.

1998-01-20

[Bioorg. Med. Chem. Lett. 8(2) , 121-6, (1998)]

Bisantrene in advanced, hormone-resistant carcinoma of the prostate: an Illinois Cancer Council phase II study.

1990-08-01

[Invest. New Drugs 8(3) , 313-5, (1990)]